Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ketamine hydrochloride - powder - 1mg/1mg

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

randlab australia pty ltd - ketamine hydrochloride - unknown - ketamine hydrochloride anaesthetic active 0.0 - active constituent

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - ketamine hydrochloride - unknown - ketamine hydrochloride anaesthetic active 0.0 - active constituent

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

interchem pty ltd - ketamine hydrochloride - unknown - ketamine hydrochloride anaesthetic active 0.0 - active constituent

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - ketamine hydrochloride - unknown - ketamine hydrochloride anaesthetic active 0.0 - active constituent

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - ketamine hydrochloride - unknown - ketamine hydrochloride anaesthetic active 0.0 - active constituent

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

janssen pharmaceuticals inc. - esketamine hydrochloride (unii: l8p1h35p2z) (esketamine - unii:50lfg02txd) - spravato ® is indicated, in conjunction with an oral antidepressant, for the treatment of: - treatment-resistant depression (trd) in adults - depressive symptoms in adults with major depressive disorder (mdd) with acute suicidal ideation or behavior limitations of use: - the effectiveness of spravato in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated [see clinical studies (14.2)] . use of spravato does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of spravato. - spravato is not approved as an anesthetic agent. the safety and effectiveness of spravato as an anesthetic agent have not been established. spravato is contraindicated in patients with: - aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation [see warnings and precautions (5.7)] - history of intracere

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

henry schein animal health - ketamine hydrochloride (unii: o18yuo0i83) (ketamine - unii:690g0d6v8h) - ketathesia™ (ketamine hydrochloride injection, usp) may be used in cats for restraint or as the sole anesthetic agent for diagnostic or minor, brief, surgical procedures that do not require skeletal muscle relaxation. it may be used in subhuman primates for restraint. ketamine hydrochloride is contraindicated in cats and subhuman primates suffering from renal or hepatic insufficiency. ketamine hydrochloride is detoxified by the liver and excreted by the kidneys; therefore, any preexistent hepatic or renal pathology or impairment of function can be expected to result in prolonged anesthesia; related fatalities have been reported.

Zimbabwe - angielski - Medicines Control Authority

rotexmedica gmbh - ketamine hydrochloride - injectable; injection - 50mg/ml

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - ketamine hydrochloride - unknown - ketamine hydrochloride anaesthetic active 0.0 - active constituent